Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2019

01-09-2019 | Streptococci | Original Article

Probabilistic chemotherapy in knee and hip replacement infection: the place of linezolid

Authors: Luc Deroche, Chloé Plouzeau, Pascale Bémer, Didier Tandé, Anne Sophie Valentin, Anne Jolivet-Gougeon, Carole Lemarié, Laurent Bret, Marie Kempf, Geneviève Héry-Arnaud, Stéphane Corvec, Christophe Burucoa, Cédric Arvieux, Louis Bernard, and the CRIOGO (Centre de Référence des Infections Ostéo-articulaires du Grand Ouest) Study Group

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2019

Login to get access

Abstract

Prosthetic joint infection (PJI) can occur with a wide range of microorganisms and clinical features. After replacement surgery of prosthetic joint, prescription of probabilistic broad-spectrum antimicrobial therapy is usual, while awaiting microbial culture results. The aim of our study was to describe the antibiotic susceptibility of microorganisms isolated from hip and knee PJI. The data were collected to determine the best alternative to the usual combination of piperacillin-tazobactam (TZP) or cefotaxime (CTX) and vancomycin (VAN). Based on a French prospective, multicenter study, we analyzed microbiological susceptibility to antibiotics of 183 strains isolated from patients with confirmed hip or knee PJI. In vitro susceptibility was evaluated: TZP+VAN, TZP+linezolid (LZD), CTX+VAN, and CTX+LZD. We also analyzed resistance to different antibiotics commonly used as oral alternatives. Among the 183 patients with PJI, 62 (34%) had a total knee prosthesis, and 121 (66%) a hip prosthesis. The main identified bacteria were Staphylococcus aureus (32.2% of isolates), coagulase-negative staphylococci (27.3%), Enterobacteriaceae (14.2%), and Streptococcus (13.7%). Infections were polymicrobial for 28 (15.3%) patients. All combinations were highly effective: CTX+VAN, CTX+LZD, TZP+VAN, and TZP+LZD (93.4%, 94%, 98.4%, and 98.9% of all cases respectively). Use of LZD instead of VAN in combination with a broad-spectrum beta-lactam covers almost all of the bacteria isolated in PJI. This association should be considered in probabilistic chemotherapy, as it is particularly easy to use (oral administration and no vancomycin monitoring).
Literature
1.
go back to reference 2016. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – surgical site infections 2016. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – surgical site infections
2.
go back to reference Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1–e25CrossRef Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1–e25CrossRef
3.
go back to reference Esposito S, Leone S, Bassetti M, Borrè S, Leoncini F, Meani E, Venditti M, Mazzotta F, Bone Joint Infections Committee for the Italian Society of Infectious Tropical Diseases (SIMIT) (2009) Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 37:478–496CrossRefPubMed Esposito S, Leone S, Bassetti M, Borrè S, Leoncini F, Meani E, Venditti M, Mazzotta F, Bone Joint Infections Committee for the Italian Society of Infectious Tropical Diseases (SIMIT) (2009) Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 37:478–496CrossRefPubMed
4.
go back to reference Spilf Orgn (2010) Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Med Mal Infect 40:185–211CrossRef Spilf Orgn (2010) Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Med Mal Infect 40:185–211CrossRef
5.
go back to reference Bémer P, Plouzeau C, Tande D, Léger J, Giraudeau B, Valentin AS, Jolivet-Gougeon A, Vincent P, Corvec S, Gibaud S, Juvin ME, Héry-Arnaud G, Lemarié C, Kempf M, Bret L, Quentin R, Coffre C, de Pinieux G, Bernard L, Burucoa C, Team the Centre de référence des Infections Ostéo-articulaires du Grand Ouest (CRIOGO) S (2014) Evaluation of 16S rRNA gene PCR sensitivity and specificity for diagnosis of prosthetic joint infection: a prospective multicenter cross-sectional study. J Clin Microbiol 52:3583–3589CrossRefPubMedPubMedCentral Bémer P, Plouzeau C, Tande D, Léger J, Giraudeau B, Valentin AS, Jolivet-Gougeon A, Vincent P, Corvec S, Gibaud S, Juvin ME, Héry-Arnaud G, Lemarié C, Kempf M, Bret L, Quentin R, Coffre C, de Pinieux G, Bernard L, Burucoa C, Team the Centre de référence des Infections Ostéo-articulaires du Grand Ouest (CRIOGO) S (2014) Evaluation of 16S rRNA gene PCR sensitivity and specificity for diagnosis of prosthetic joint infection: a prospective multicenter cross-sectional study. J Clin Microbiol 52:3583–3589CrossRefPubMedPubMedCentral
6.
go back to reference Takoudju E, Bemer P, Touchais S, Asseray N, Corvec S, Khatchatourian L, Serandour N, Boutoille D, Nantes Bone and Joint Infections Study Group (2018) Bacteriological relevance of linezolid versus vancomycin in postoperative empirical treatment of osteoarticular infections: a retrospective single-center study. Int J Antimicrob Agents Takoudju E, Bemer P, Touchais S, Asseray N, Corvec S, Khatchatourian L, Serandour N, Boutoille D, Nantes Bone and Joint Infections Study Group (2018) Bacteriological relevance of linezolid versus vancomycin in postoperative empirical treatment of osteoarticular infections: a retrospective single-center study. Int J Antimicrob Agents
7.
go back to reference Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL (2018) Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med 46:12–20CrossRef Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL (2018) Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med 46:12–20CrossRef
8.
go back to reference Rutter WC, Burgess DS (2018) Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother 62 Rutter WC, Burgess DS (2018) Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother 62
9.
10.
go back to reference Titécat M, Senneville E, Wallet F, Dezèque H, Migaud H, Courcol RJ, Loïez C (2015) Microbiologic profile of staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect 16:77–83CrossRef Titécat M, Senneville E, Wallet F, Dezèque H, Migaud H, Courcol RJ, Loïez C (2015) Microbiologic profile of staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect 16:77–83CrossRef
11.
go back to reference Cremniter J, Slassi A, Quincampoix J-C, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann J-L, Gaillard J-L, Rottman M (2010) Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 48:1428–1431CrossRefPubMedPubMedCentral Cremniter J, Slassi A, Quincampoix J-C, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann J-L, Gaillard J-L, Rottman M (2010) Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 48:1428–1431CrossRefPubMedPubMedCentral
12.
13.
go back to reference Wald-Dickler N, Holtom P, Spellberg B (2018) Busting the myth of “Static vs Cidal”: a systemic literature review. Clin Infect Dis 66:1470–1474CrossRefPubMed Wald-Dickler N, Holtom P, Spellberg B (2018) Busting the myth of “Static vs Cidal”: a systemic literature review. Clin Infect Dis 66:1470–1474CrossRefPubMed
14.
go back to reference Beekmann SE, Gilbert DN, Polgreen PM (2008) Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 62:407–410CrossRefPubMed Beekmann SE, Gilbert DN, Polgreen PM (2008) Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 62:407–410CrossRefPubMed
15.
go back to reference Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB (2014) Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 58:2334–2343CrossRefPubMedPubMedCentral Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB (2014) Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 58:2334–2343CrossRefPubMedPubMedCentral
16.
go back to reference Pettigrew M, Thirion DJ, Libman M, Zanotti G (2012) Cost comparison of linezolid versus vancomycin for treatment of complicated skin and skin-structure infection caused by methicillin-resistant Staphylococcus aureus in Quebec. Can J Infect Dis Med Microbiol 23:187–195CrossRefPubMedPubMedCentral Pettigrew M, Thirion DJ, Libman M, Zanotti G (2012) Cost comparison of linezolid versus vancomycin for treatment of complicated skin and skin-structure infection caused by methicillin-resistant Staphylococcus aureus in Quebec. Can J Infect Dis Med Microbiol 23:187–195CrossRefPubMedPubMedCentral
17.
go back to reference Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen C-I, Hajek P, Patel DA, Gao X (2014) Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant Staphylococcus aureus confirmed nosocomial pneumonia in China. Value Health Reg Issues 3:94–100CrossRefPubMed Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen C-I, Hajek P, Patel DA, Gao X (2014) Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant Staphylococcus aureus confirmed nosocomial pneumonia in China. Value Health Reg Issues 3:94–100CrossRefPubMed
18.
go back to reference Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK (2018) ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J Antimicrob Chemother 73:1880–1887CrossRefPubMed Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK (2018) ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J Antimicrob Chemother 73:1880–1887CrossRefPubMed
19.
go back to reference Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK. (2017) Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important Gram-positive cocci in the United States from the LEADER Surveillance Program (2011 to 2015). Antimicrob Agents Chemother 61 Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK. (2017) Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important Gram-positive cocci in the United States from the LEADER Surveillance Program (2011 to 2015). Antimicrob Agents Chemother 61
20.
21.
go back to reference Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM (2013) The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4–11CrossRefPubMed Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM (2013) The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4–11CrossRefPubMed
22.
go back to reference Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, Zhang R, Li J, Zhao Q, He T, Wang D, Wang Z, Shen Y, Li Y, Feßler AT, Wu C, Yu H, Deng X, Xia X, Shen J (2015) A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 70:2182–2190CrossRefPubMed Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, Zhang R, Li J, Zhao Q, He T, Wang D, Wang Z, Shen Y, Li Y, Feßler AT, Wu C, Yu H, Deng X, Xia X, Shen J (2015) A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 70:2182–2190CrossRefPubMed
23.
go back to reference Antonelli A, D’Andrea MM, Brenciani A, Galeotti CL, Morroni G, Pollini S, Varaldo PE, Rossolini GM (2018) Characterization of poxtA, a novel phenicol–oxazolidinone–tetracycline resistance gene from an MRSA of clinical origin. J Antimicrob Chemother 73:1763–1769CrossRefPubMed Antonelli A, D’Andrea MM, Brenciani A, Galeotti CL, Morroni G, Pollini S, Varaldo PE, Rossolini GM (2018) Characterization of poxtA, a novel phenicol–oxazolidinone–tetracycline resistance gene from an MRSA of clinical origin. J Antimicrob Chemother 73:1763–1769CrossRefPubMed
24.
go back to reference Weßels C, Strommenger B, Klare I, Bender J, Messler S, Mattner F, Krakau M, Werner G, Layer F. Emergence and control of linezolid-resistant Staphylococcus epidermidis in an ICU of a German hospital. J Antimicrob Chemother Weßels C, Strommenger B, Klare I, Bender J, Messler S, Mattner F, Krakau M, Werner G, Layer F. Emergence and control of linezolid-resistant Staphylococcus epidermidis in an ICU of a German hospital. J Antimicrob Chemother
25.
go back to reference Dortet L, Glaser P, Kassis-Chikhani N, Girlich D, Ichai P, Boudon M, Samuel D, Creton E, Imanci D, Bonnin R, Fortineau N, Naas T (2018) Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France. J Antimicrob Chemother 73:41–51CrossRefPubMed Dortet L, Glaser P, Kassis-Chikhani N, Girlich D, Ichai P, Boudon M, Samuel D, Creton E, Imanci D, Bonnin R, Fortineau N, Naas T (2018) Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France. J Antimicrob Chemother 73:41–51CrossRefPubMed
26.
go back to reference Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre M-Á, Fereres J, Sánchez-García M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821–825CrossRefPubMed Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre M-Á, Fereres J, Sánchez-García M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821–825CrossRefPubMed
27.
go back to reference Li X, Arias CA, Aitken SL, Galloway Peña J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S, DebRoy S, Bhatti MM, Simmons DE, Raad I, Hachem R, Folan SA, Sahasarabhojane P, Kalia A, Shelburne SA (2018) Clonal emergence of invasive multidrug-resistant Staphylococcus epidermidis deconvoluted via a combination of whole-genome sequencing and microbiome analyses. Clin Infect Dis 67:398–406CrossRefPubMedPubMedCentral Li X, Arias CA, Aitken SL, Galloway Peña J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S, DebRoy S, Bhatti MM, Simmons DE, Raad I, Hachem R, Folan SA, Sahasarabhojane P, Kalia A, Shelburne SA (2018) Clonal emergence of invasive multidrug-resistant Staphylococcus epidermidis deconvoluted via a combination of whole-genome sequencing and microbiome analyses. Clin Infect Dis 67:398–406CrossRefPubMedPubMedCentral
Metadata
Title
Probabilistic chemotherapy in knee and hip replacement infection: the place of linezolid
Authors
Luc Deroche
Chloé Plouzeau
Pascale Bémer
Didier Tandé
Anne Sophie Valentin
Anne Jolivet-Gougeon
Carole Lemarié
Laurent Bret
Marie Kempf
Geneviève Héry-Arnaud
Stéphane Corvec
Christophe Burucoa
Cédric Arvieux
Louis Bernard
and the CRIOGO (Centre de Référence des Infections Ostéo-articulaires du Grand Ouest) Study Group
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-019-03594-z

Other articles of this Issue 9/2019

European Journal of Clinical Microbiology & Infectious Diseases 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine